Literature DB >> 20681002

Racial and ethnic disparities in cardiovascular medication use among older adults in the United States.

Dima M Qato1, Stacy Tessler Lindau, Rena M Conti, L Philip Schumm, G Caleb Alexander.   

Abstract

BACKGROUND: Despite persistent racial/ethnic disparities in cardiovascular disease (CVD) among older adults, information on whether there are similar disparities in the use of prescription and over-the-counter medications to prevent such disease is limited. We examined racial and ethnic disparities in the use of statins and aspirin among older adults at low, moderate, and high risk for CVD. METHODS AND
RESULTS: In-home interviews, including a medication inventory, were administered between June 2005 and March 2006 to 3005 community-residing individuals, ages 57-85 years, drawn from a cross-sectional, nationally-representative probability sample of the United States. Based on a modified version of the Adult Treatment Panel III (ATP III) risk stratification guidelines, 1066 respondents were at high cardiovascular risk, 977 were at moderate risk, and 812 were at low risk. Rates of use were highest among respondents at high cardiovascular risk. Racial differences were highest among respondents at high risk with blacks less likely than whites to use statins (38% vs. 50%, p = 0.007) and aspirin (29% vs. 44%, p = 0.008). After controlling for age, gender, comorbidity, and socioeconomic, and access to care factors, racial/ethnic disparities persisted. In particular, blacks at highest risk were less likely than their white counterparts to use statins (odds ratio (OR) 0.65, confidence interval (CI) 0.46-0.90) or aspirin (OR 0.61, CI 0.37-0.98).
CONCLUSIONS: These results, based on an in-home survey of actual medication use, suggest widespread underuse of indicated preventive therapies among older adults at high cardiovascular risk in the United States. Racial/ethnic disparities in such use may contribute to documented disparities in cardiovascular outcomes. 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20681002      PMCID: PMC3586253          DOI: 10.1002/pds.1974

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  46 in total

1.  Transforming insurance coverage into quality health care: voltage drops from potential to delivered quality.

Authors:  J M Eisenberg; E J Power
Journal:  JAMA       Date:  2000-10-25       Impact factor: 56.272

2.  Disparities in health care by race, ethnicity, and language among the insured: findings from a national sample.

Authors:  Kevin Fiscella; Peter Franks; Mark P Doescher; Barry G Saver
Journal:  Med Care       Date:  2002-01       Impact factor: 2.983

3.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

Review 4.  Use of statins and aspirin to reduce risks of cardiovascular disease.

Authors:  Patricia R Hebert; Marc A Pfeffer; Charles H Hennekens
Journal:  J Cardiovasc Pharmacol Ther       Date:  2002-04       Impact factor: 2.457

Review 5.  An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program.

Authors:  B J Ansell; K E Watson; A M Fogelman
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

6.  Racial disparities in the quality of care for enrollees in medicare managed care.

Authors:  Eric C Schneider; Alan M Zaslavsky; Arnold M Epstein
Journal:  JAMA       Date:  2002-03-13       Impact factor: 56.272

7.  Aspirin for primary prevention. Doctors and patients should understand potential benefits and risks of aspirin treatment.

Authors:  A Alkhenizan
Journal:  BMJ       Date:  2000-12-09

8.  Long-term persistence in use of statin therapy in elderly patients.

Authors:  Joshua S Benner; Robert J Glynn; Helen Mogun; Peter J Neumann; Milton C Weinstein; Jerry Avorn
Journal:  JAMA       Date:  2002 Jul 24-31       Impact factor: 56.272

9.  Trends in hypercholesterolemia, treatment and control among United States adults.

Authors:  Earl S Ford; Chaoyang Li; William S Pearson; Guixiang Zhao; Ali H Mokdad
Journal:  Int J Cardiol       Date:  2008-12-10       Impact factor: 4.164

10.  Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events.

Authors:  Steven M Weisman; David Y Graham
Journal:  Arch Intern Med       Date:  2002-10-28
View more
  27 in total

1.  Just because it's low cost doesn't mean it's accessible.

Authors:  Dima M Qato; G Caleb Alexander
Journal:  J Gen Intern Med       Date:  2012-10       Impact factor: 5.128

2.  A National Assessment of Medication Adherence to Statins by the Racial Composition of Neighborhoods.

Authors:  Andrew M Davis; Michael S Taitel; Jenny Jiang; Dima M Qato; Monica E Peek; Chia-Hung Chou; Elbert S Huang
Journal:  J Racial Ethn Health Disparities       Date:  2016-06-28

3.  Pharmacy accessibility and cost-related underuse of prescription medications in low-income Black and Hispanic urban communities.

Authors:  Dima Mazen Qato; Jocelyn Wilder; Shannon Zenk; Andrew Davis; Jennifer Makelarski; Stacy Tessler Lindau
Journal:  J Am Pharm Assoc (2003)       Date:  2017-01-30

4.  Race, ethnicity, and state-by-state geographic variation in hemorrhagic stroke in dialysis patients.

Authors:  James B Wetmore; Milind A Phadnis; Jonathan D Mahnken; Edward F Ellerbeck; Sally K Rigler; Xinhua Zhou; Theresa I Shireman
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-23       Impact factor: 8.237

5.  Overuse of antidepressants in a nationally representative adult patient population in 2005.

Authors:  Rena Conti; Alisa B Busch; David M Cutler
Journal:  Psychiatr Serv       Date:  2011-07       Impact factor: 3.084

6.  Impact of race on cumulative exposure to antihypertensive medications in dialysis.

Authors:  James B Wetmore; Jonathan D Mahnken; Sally K Rigler; Edward F Ellerbeck; Purna Mukhopadhyay; Qingjiang Hou; Theresa I Shireman
Journal:  Am J Hypertens       Date:  2012-12-28       Impact factor: 2.689

7.  Methods for estimation of disparities in medication use in an observational cohort study: results from the Multi-Ethnic Study of Atherosclerosis.

Authors:  Robyn L McClelland; Neal W Jorgensen; Wendy S Post; Moyses Szklo; Richard A Kronmal
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-02-04       Impact factor: 2.890

8.  Effects of the 2013 American College of Cardiology/American Heart Association guidelines on racial and ethnic disparities in statin treatment among diabetics.

Authors:  Gregory A Phelps; Yanru Qiao; Merrion G Buckley; Junling Wang; Minghui Sam Li; Soumitra S Bhuyan; Marie A Chisholm-Burns
Journal:  Res Social Adm Pharm       Date:  2019-07-25

9.  Racial differences in antilipemic use and lipid control in high-risk older adults: post-Medicare Part D.

Authors:  Joseph T Hanlon; Robert M Boudreau; Subashan Perera; Elsa S Strotmeyer; Anne B Newman; Eleanor M Simonsick; Ronald I Shorr; Douglas C Bauer; Julie M Donohue
Journal:  Am Heart J       Date:  2013-08-28       Impact factor: 4.749

10.  Patient weighting of osteoporosis medication attributes across racial and ethnic groups: a study of osteoporosis medication preferences using conjoint analysis.

Authors:  S Silverman; A Calderon; K Kaw; T B Childers; B A Stafford; W Brynildsen; A Focil; M Koenig; D T Gold
Journal:  Osteoporos Int       Date:  2012-12-18       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.